NDLI: A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Tsuritani, Shinji Nozaki, Tetsuo Okumura, Akiou Kimura, Hitomi Kazama, Taizo
Spatial Coverage	Japan
Description	Author Affiliation: Tsuritani S ( Department of Urology, Kurobe City Hospital, Kurobe, Japan. turi2202 @ yahoo.co.jp)
Abstract	INTRODUCTION: We examined the tolerability of dosage methods of naftopidil in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH/male LUTS). PATIENTS AND METHODS: A total of 80 patients with BPH/male LUTS who had an International Prostate Symptom Score (IPSS) >or=8 and IPSS quality of life (QoL) >or=2 were enrolled and randomly administered naftopidil for 8 weeks at either 75 mg once daily (OD) in the evening (group O; n = 41) or 25 mg thrice daily (TID) in the morning, afternoon and evening (group T; n = 39). RESULTS: IPSS total score, IPSS-QoL and BPH impact index (BII) were significantly improved for both groups at 8 weeks after starting treatment compared to baseline. IPSS total score and daytime and 24-hour voiding frequencies were significantly improved at 8 weeks after starting treatment for group O in comparison to group T. Group O showed a significantly better degree of change in BII in comparison to group T. CONCLUSIONS: Naftopidil 75 mg OD in the evening was better tolerated than naftopidil 25 mg TID for the objective parameter and BII.
File Format	HTM / HTML
ISSN	00421138
Issue Number	1
Volume Number	85
e-ISSN	14230399
Journal	Urologia Internationalis
Language	English
Publisher	Karger
Publisher Date	2010-01-01
Publisher Place	Switzerland
Access Restriction	Subscribed
Subject Keyword	Discipline Urology Adrenergic Alpha-1 Receptor Antagonists Administration & Dosage Naphthalenes Piperazines Prostatic Hyperplasia Drug Therapy Urination Disorders Adverse Effects Aged Aged, 80 And Over Drug Administration Schedule Humans Japan Male Middle Aged Prospective Studies Complications Quality Of Life Severity Of Illness Index Time Factors Treatment Outcome Etiology Physiopathology Urodynamics Drug Effects Comparative Study Journal Article Multicenter Study Randomized Controlled Trial
Content Type	Text
Resource Type	Article
Subject	Urology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in